Pune Based Serum Institute Of India To Produce 10 Crore Doses Of Covishield Vaccine A Month From 2021

Pune Based Serum Institute Of India To Produce 10 Crore Doses Of Covishield Vaccine A Month From 2021Serum Institute of India (Pic Via Twitter)

Leading the vaccinal route to defeat the COVID-19 pandemic, Pune based Serum Institute of India (SII) is set to significantly expand its manufacturing of the Covishield vaccine developed by the University of Oxford and pharmaceutical giant AstraZeneca, reports Livemint.

Having already produced five crore doses of the said vaccine, the Adar Poonawalla led SII is now aiming to manufacture 10 crore doses of the vaccine each month starting 2021. This gains significance as the company has already applied to the Indian regulator, Drug Controller General of India (DCGI) for an emergency use authorisation (EUA).

As per details shared by Poonawalla, SII is working to increase its capacity to produce as many as 250 crore doses a year by the end of 2021. The company has already expanded its capacity to produce as many as 150 crore vaccines annually.

It should be noted that Poonawalla has already stated that for SII, which is the world's largest vaccine maker, India shall be the priority market for the delivery of Covishield stocks, following which it would look to supply stocks to COVAX batch of nations which are mainly based in Africa.